Register to chat with like-minded investors on our interactive forums.
The current GBY market cap is 425.01M. The company's latest EPS is USD -1.2357 and P/E is -1.72.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 102.43M | 118.19M | 110.7M | 111.3M | 176.23M |
| Operating Income | -105.18M | -129.55M | -183.34M | -201.28M | -208.48M |
| Net Income | -95.19M | -121M | -178.29M | -192.28M | -257.83M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 637.52M | 938.55M | 721.92M | 562.51M | 165.32M |
| Total Liabilities | 204.78M | 441.18M | 346.58M | 267.55M | 82.43M |
| Total Equity | 432.74M | 497.37M | 375.34M | 294.96M | 82.89M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -144.4M | 169.88M | -233.25M | -223.63M | -224.84M |
| Investing | -59.8M | -271.63M | 248.2M | 59.29M | 153.53M |
| Financing | 142.03M | 153.1M | 32.86M | 84.66M | 14.59M |
| Market Cap | 425.01M |
| Price to Earnings Ratio | -1.72 |
| Price to Sales Ratio | 2.51 |
| Price to Cash Ratio | 9.78 |
| Price to Book Ratio | 5.34 |
| Dividend Yield | - |
| Shares Outstanding | 208.65M |
| Average Volume (1 week) | 41.05k |
| Average Volume (1 Month) | 84.45k |
| 52 Week Change | 486.86% |
| 52 Week High | 2.9435 |
| 52 Week Low | 0.2901 |
| Spread (Intraday) | 0.05 (2.42%) |
| Company Name | Sangamo Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.sangamo.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
